The Biphasic Delivery Platform.
A patented immediate-release / delayed-release oral delivery architecture engineered to optimize the pharmacokinetic performance of short half-life pharmaceuticals — from a single, once-daily dosage form.
Short half-life drugs are commercially constrained.
Many clinically valuable small-molecule drugs share a common limitation: a short plasma half-life. Standard immediate-release formulations rise to a rapid peak, then decline below therapeutic exposure long before the next scheduled dose.
The downstream consequences are commercial as well as clinical — multiple daily dosing, peak-to-trough fluctuations, adherence challenges, and a ceiling on differentiated product positioning.
Two engineered populations, one capsule.
The biphasic architecture co-formulates uncoated immediate-release granules with enteric-coated delayed-release beads — each tuned to release at a distinct point along the GI tract.
- IR granulesUncoated, dissolve on contact in the stomach.
- DR beadspH-triggered enteric coating delays release until the targeted intestinal window.
How the biphasic platform works.
A live walk-through of a single dosage form — from administration through to a complete dual-peak pharmacokinetic profile.
- Stage 01Administration
A single oral dose is taken
One capsule, once a day. Inside: two engineered drug populations sitting side-by-side — an immediate-release fraction and an enteric-protected delayed-release fraction.
- Stage 02Stomach environment
Immediate-release phase begins
Within minutes, the IR layer dissolves in gastric fluid. Drug particles disperse and free molecules begin entering the bloodstream — establishing therapeutic coverage almost immediately.
Onset · 0–30 min - Stage 03Upper GI absorption
First plasma peak rises
Released drug crosses the intestinal epithelium and enters systemic circulation. Plasma concentration climbs through Peak #1 — the immediate-release event.
Peak #1 — IR - Stage 04Protected transit
Delayed-release component stays intact
The DR beads are shielded by a pH-responsive enteric coating. They resist gastric acid and continue through the GI tract, payload preserved.
Gastric protection - Stage 05Secondary release
Targeted dissolution at the absorption window
On reaching the targeted intestinal pH, the polymer coat dissolves and the DR fraction unloads — a second wave of drug molecules enters circulation hours after the first.
Peak #2 — DR - Stage 06Dual-peak pharmacokinetics
Sustained therapeutic exposure across the day
Two engineered peaks combine into a single 24-hour exposure profile — smoother peak-to-trough, fewer doses, differentiated product positioning.
24-hour coverage
Releasing the second dose where the drug is actually absorbed.
Many small molecules have a narrow region of the GI tract where bioavailability is maximized. The platform programs the delayed-release phase to dissolve precisely within that window — protecting potency and preserving exposure.
From single peak to sustained dual-peak coverage.
Conventional formulation. Rapid peak, rapid decline below therapeutic threshold.
Single delayed peak. Late onset; no early therapeutic coverage.
Two engineered peaks. Sustained exposure across the full dosing interval.
A flexible pharmaceutical delivery architecture.
The platform was designed to support multiple formulation strategies and future product opportunities — not a single fixed product. Hover any component to explore.
pH-responsive polymer coatings (e.g. methacrylic acid copolymers) that remain intact in gastric acid and dissolve above pH ~5.5, protecting the delayed-release payload until it reaches the small intestine.
From a single product to a platform technology.
Most patents protect one molecule, one product. The biphasic architecture is engineered as a platform — the same delivery system applies across many compounds, formulations, and therapeutic areas.
- 01Traditional Patent
- 02One Molecule
- 03One Product
- 01Biphasic Platform
- 02Multiple Molecules
- 03Multiple Formulations
- 04Multiple Therapeutic Areas
- 05Multiple Product Opportunities
Clinical performance. Commercial differentiation.
The biphasic platform is a vehicle for re-engineering the value of established and developmental molecules — improving the patient experience while unlocking new product positioning.
The Future of Combination Therapy.
The biphasic delivery platform is designed not only to optimize individual compounds, but also to enable differentiated combination therapies built around established pharmaceutical agents.
- Metformin Tablet
- SGLT2 Tablet
- Two Separate Products
- Multiple Dosing Events
- Lower Convenience
- Biphasic Combination Platform
- Single Oral Dose
- Immediate Release Component
- Delayed Release Component
- Coordinated Therapeutic Exposure
- Differentiated Product
Engineering Therapeutic Sequencing.
The biphasic platform may enable pharmaceutical developers to engineer the timing and sequence of drug exposure within a single dosage form — creating opportunities for innovative formulations that go beyond simply combining multiple drugs into one tablet.
From Two Products To One Platform.
What today's market treats as two commodity prescriptions, the biphasic platform can potentially convert into a single, differentiated, IP-protected product.
One platform. An entire metabolic disease ecosystem.
Hover any category to see how the biphasic platform could support future product development opportunities across the metabolic disease landscape.
Disease
The strategic core: differentiated multi-agent products from a single oral platform.
Designed For The Next Generation Of Combination Therapies.
The platform may support the development of combination therapies where multiple agents are commonly prescribed together — delivering each component on its optimal release schedule from a single dosage form.
A Platform Technology, Not A Single Product.
The value of the patent lies in its ability to support the development of multiple differentiated pharmaceutical products across numerous therapeutic categories.
Platform™
Explore where this platform could fit.
See the therapeutic categories, product opportunities, and licensing pathways enabled by the biphasic platform.